Dr. Rosenberg has pioneered the development of immunotherapy that has resulted in the first effective immunotherapies for selected patients with advanced cancer. He has also pioneered the development of gene therapy and was the first to successfully insert foreign genes into humans and to conduct clinical studies of the gene therapy of cancer. More recently he and his research group have cloned the genes encoding cancer regression antigens and have used these to develop cancer vaccines for the treatment of patients with metastatic melanoma. His recent studies of cell transfer therapies have resulted in cancer regressions in patients associated with the clonal repopulation of lymphocytes with anti-tumor reactivity.
Dr. Rosenberg is Chief of Surgery at the National Cancer Institute in Bethesda, MD and a Professor of Surgery at the Uniformed Services University of Health Sciences and at the George Washington University School of Medicine and Health Sciences in Washington, DC.
(Biography as of November 2005)
